Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Brainstem01:19

Brainstem

7.4K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
7.4K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

508
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
508

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired reward sensitivity in Parkinson's depression is unresponsive to dopamine treatment.

Brain : a journal of neurology·2025
Same author

Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease.

Nature. Mental health·2024
Same author

Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson's disease.

medRxiv : the preprint server for health sciences·2023
Same author

Longitudinal decline in striatal dopamine transporter binding in Parkinson's disease: associations with apathy and anhedonia.

Journal of neurology, neurosurgery, and psychiatry·2023
Same author

Lack of Association of Group A Streptococcal Infections and Onset of Tics: European Multicenter Tics in Children Study.

Neurology·2022
Same author

Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study.

Journal of neurology, neurosurgery, and psychiatry·2020

Related Experiment Video

Updated: Mar 5, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.3K

Parkinson disease.

Werner Poewe1, Klaus Seppi1, Caroline M Tanner2,3

  • 1Department of Neurology, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

Nature Reviews. Disease Primers
|March 24, 2017
PubMed
Summary
This summary is machine-generated.

Parkinson disease, a common neurodegenerative disorder, involves dopamine deficiency and alpha-synuclein aggregates. Early diagnosis and novel therapies targeting alpha-synuclein are crucial for managing this condition.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.1K

Related Experiment Videos

Last Updated: Mar 5, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.3K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.1K

Area of Science:

  • Neuroscience
  • Neurology

Background:

  • Parkinson disease (PD) is the second most prevalent neurodegenerative disorder, affecting 2-3% of individuals over 65.
  • Key neuropathological features include substantia nigra neuronal loss, striatal dopamine deficiency, and alpha-synuclein (α-synuclein) protein aggregates.
  • PD impacts various cell types in the central and peripheral nervous systems, presenting with both motor and non-motor symptoms.

Purpose of the Study:

  • To review the current understanding of Parkinson disease pathogenesis, diagnosis, and treatment.
  • To highlight recent advancements in diagnostic biomarkers and experimental therapies.
  • To emphasize the need for identifying prodromal markers for early intervention.

Main Methods:

  • Review of existing literature on Parkinson disease.
  • Analysis of neuroimaging techniques (PET, SPECT, MRI) for diagnostic aid.
  • Examination of current and experimental therapeutic strategies.

Main Results:

  • Neuroimaging modalities show promise in aiding early and differential diagnosis of PD.
  • Current treatments focus on dopamine replacement and symptom management, with deep brain stimulation for advanced cases.
  • Experimental therapies are exploring gene-based, cell-based approaches, and targeting α-synuclein aggregation and transport.

Conclusions:

  • Parkinson disease pathogenesis is multifactorial, involving α-synuclein, mitochondrial dysfunction, oxidative stress, and neuroinflammation.
  • Effective management requires addressing both motor and non-motor symptoms.
  • Identifying prodromal markers is essential for initiating disease-modifying therapies earlier in the disease course.